3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist

The article argues Pfizer, T. Rowe Price and Verizon are undervalued despite company-specific headwinds, highlighting forward dividend yields of 5.6%, 5.0% and 6.2%, respectively. Pfizer trades at 9.6 times forward earnings, T. Rowe Price at 10 times, and Verizon below 9 times; Pfizer faces post-COVID revenue declines and patent expirations, while T. Rowe Price is shifting toward ETFs. Verizon reported 550,000 net mobility and broadband customer additions in Q2 2026, up more than 230,000 year over year, and operating cash flow rose nearly 10%.

Analysis

The common risk is yield anchoring: attractive payouts can support a floor, but they do not offset deteriorating cash-flow durability. Pfizer is the most binary case. A rerating requires clinical and commercial validation of replacement products before legacy-drug erosion overwhelms COVID normalization; pipeline headlines alone are not enough. Verify trial readouts, launch economics, and free-cash-flow coverage of the dividend. T. Rowe Price has a less binary but structural challenge: ETF growth may retain assets, yet success depends on whether it can win distribution and preserve fee economics as assets migrate from higher-fee active products. A market drawdown would test both AUM resilience and the payout thesis. Verizon’s satellite threat is likely to be more relevant first in coverage gaps and niche use cases than as an immediate substitute for mainstream cellular service; the nearer-term test is whether customer additions and cost savings persist while network investment and debt service absorb cash. SpaceX competition could still pressure pricing or increase required investment before it materially takes subscribers.

Near term, the article’s positive framing may support a yield-driven relief trade, but the 1–3 month catalyst path is company-specific execution, not valuation alone. Over 6–18 months, Pfizer faces pipeline/patent timing, T. Rowe faces product-mix economics, and Verizon faces competitive response and capital intensity. The contrarian risk is that “cheap” reflects lower normalized earnings, not mispricing. No valuation claim should be acted on without checking current prices, earnings estimates, and cash-flow data.

Key Decisions for Investors

• Prefer a staged TROW position over a broad three-name basket if seeking dividend exposure: the thesis is ETF asset conversion and payout durability, not simply a low multiple. Reassess if ETF net flows lag or fee revenue per AUM falls faster than costs.
• Keep PFE as a catalyst-sized position rather than a yield substitute. Add only after verifying trial data and updated guidance support replacement revenue; cut the thesis if pipeline setbacks coincide with weaker free-cash-flow dividend coverage or a material payout reset.
• Treat VZ as a monitored income/recovery trade, not a proven satellite-disruption short. Track post-quarter subscriber trends, service revenue/pricing, capital expenditure, and cash flow; reconsider if customer additions reverse or competitive response requires sustained incremental investment.
• Avoid shorting SpaceX or buying options solely on the article’s competitive framing. The missing evidence is measurable subscriber churn, pricing impact, and timing of direct substitution; use those as alerts before expressing a relative-value trade.